CLEVIPREX 0.5 MG — DIN 02366223
CLEVIDIPINE : 0.5 MG · CHIESI FARMACEUTICI S.P.A. · EMULSION · wholesale supply in Canada
Health Canada status: MARKETED
What is CLEVIPREX?
CLEVIPREX 0.5 MG contains CLEVIDIPINE : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02366223, held by CHIESI FARMACEUTICI S.P.A., supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 04-Aug-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CLEVIPREX used for?
Management of acute elevation of blood pressure in perioperative settings.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does clevidipine cost around the world?
clevidipine is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. South Africa publishes a single exit price; United Arab Emirates publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 1 | 2 | ZAR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
3 pack listings across 2 brand entries and 2 price bases, refreshed 01 Sep 2026. Ranges span every clevidipine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.5 MG |
|---|---|
| Dosage form | EMULSION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 50 mL or 100 mL single-use glass vials; available in boxes of 10 vials. |
| Storage | Not explicitly detailed in provided text (section 11 header present but content truncated), but notes 12-hour limit after puncture. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Clevidipine |
|---|---|
| ATC code | C08CA16 |
| AHFS class | 28:32.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02366223 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2366223 |
| Brand name | CLEVIPREX |
| Generic / active ingredient | CLEVIDIPINE : 0.5 MG |
| Market authorization holder | CHIESI FARMACEUTICI S.P.A. |
| Health Canada schedule | Prescription |
| ATC code | C08CA16 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C08CA |
| Current status | MARKETED |
| Status date | 04-Aug-2023 |
| Original market date | 2011-09-19 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
IV infusion only. Initial: 1-2 mg/h. Titrate by doubling dose every 90s until near target. Maintenance: 4-6 mg/h. Max: 32 mg/h. Max 1000 mL/24h. Use within 12h of puncture.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Allergy to clevidipine, soy, eggs, or peanuts; defective lipid metabolism (e.g., pathologic hyperlipidemia); severe aortic stenosis.
Warnings and precautions
Maintain strict aseptic technique (supports microbial growth). Monitor for systemic hypotension, reflex tachycardia, and rebound hypertension. Negative inotropic effects possible.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC C08CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Amlodipine | ACCEL-AMLODIPINE · ACH-AMLODIPINE · AG-AMLODIPINE · AMLODIPINE · +39 more | 138 | 67 | Yes |
| Nifedipine | ADALAT · ADALAT - CAP 10MG · ADALAT CAP 10MG · ADALAT CAP 5MG · +37 more | 60 | 12 | Yes |
| Felodipine | APO-FELODIPINE · PLENDIL · RENEDIL · RENEDIL SRT 10MG · +3 more | 17 | 8 | Yes |
| Nimodipine | NIMOTOP · NIMOTOP - CAP 30MG · NIMOTOP CAP 30MG · NIMOTOP I.V.-0.2MG/ML · +1 more | 5 | 1 | Yes |
| Clevidipine | CLEVIPREX | 1 | 1 | Yes |
| Nicardipine | CARDENE 20MG CAPSULES · CARDENE 30MG CAPSULES · CARDENE CAP 30MG | 3 | 0 | Not in Canada |
| Nifedipine, Combinations | ADALAT XL PLUS | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.